secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001493152-24-010520
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow full-year 2023 revenue $130.2M (+47% YoY), GAAP net loss widens to $24.4M; adj EBITDA $28.1M
--------------------------------------------------------------------------------

- FY2023 revenue $130.2M, up 47% YoY; GAAP net loss $24.4M (vs $14.1M loss in 2022).
- Adjusted EBITDA $28.1M, +116% YoY; cash from ops $3.8M full-year, $8.7M in Q4.
- IHEEZO Q4 reorder rate 83%; Q1 2024 sales impacted by Change Healthcare cyberattack; CMS added J-code to ASP file.
- VEVYE launch exceeding expectations; 70% refill rate; over 40M covered lives including TriCare and Aetna.
- TRIESENCE first PPQ batch scheduled for April 15; NDA transferred; price set at $944/unit; targeting 90K units inventory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224010520/0001493152-24-010520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224010520/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer